SCHEMBL14897172

SCHEMBL14897172

C[C@@H]1CN(c2ccc3ncc(C(=O)Nc4cncc(F)c4)n3n2)C[C@H](C)O1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MAP3K7 O43318 4/20 0.43
▸ IRAK4 Q9NWZ3 3/20 0.42
▸ SMO Q99835 2/20 0.37
▸ PGR P06401 1/20 0.37
▸ GPR183 P32249 1/20 0.37
▸ CLK2 P49760 3/20 0.36
▸ DYRK1A Q13627 2/20 0.36
▸ NTRK1 P04629 2/20 0.36
▸ CLK3 P49761 1/20 0.36
▸ WNT1 P04628 1/20 0.36
▸ KIT P10721 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ WDR5 P61964 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14897848 0.89 MAP3K7 (0.46) MAP3K7IRAK4NTRK1WDR5
SCHEMBL14897741 0.86 IRAK4 (0.47) IRAK4NTRK1
SCHEMBL14897155 0.85 NAMPT (0.46) MAP3K7IRAK4SMOPGRGPR183
SCHEMBL14897060 0.84 IRAK4 (0.49) IRAK4NTRK1
SCHEMBL14897058 0.84 IRAK4 (0.47) IRAK4DYRK1ANTRK1
SCHEMBL14897446 0.84 IRAK4 (0.49) IRAK4CLK2DYRK1ANTRK1CLK3
SCHEMBL14897850 0.83 ABL1 (0.46) IRAK4NTRK1
SCHEMBL14897822 0.82 IRAK4 (0.44) IRAK4NTRK1
SCHEMBL14897392 0.82 IRAK4 (0.46) IRAK4NTRK1
SCHEMBL14896864 0.82 IRAK4 (0.50) IRAK4NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2018-07-05 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
US-9957271-B2 Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2018-05-01 — — US disclosed
EP-2768509-B1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2017-03-22 — — EP disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2014-11-27 — — US disclosed
WO-2013059587-A9 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2014-10-23 — — WO disclosed
WO-2013059587-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2013-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140349993-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAP3K7 2948/4885IRAK4 3168/4885SMO 1889/4885
US-20180186801-A1 SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 MAP3K7 2948/4885IRAK4 3168/4885SMO 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback